Seres Argues Different Diagnostic Needed In Recurrent C. Difficile Trials
Executive Summary
As it talks study design with FDA, Seres says new analysis of Phase II trial of microbiome candidate SER-109 suggests that a C. difficile cytotoxin test would be more accurate and that a higher dose may be more effective.